We are live on
!
Find out more
BMO
Beck Mack & Oliver Portfolio holdings
AUM
$4.85B
1-Year Est. Return
9.66%
This Fund
S&P 500
This Quarter
Est. Return
+10.76%
1 Year Est. Return
+9.66%
3 Year Est. Return
+69.39%
5 Year Est. Return
+96.17%
10 Year Est. Return
+350.87%
AUM
$4.93B
AUM Growth
+$634M
(+15%)
Cap. Flow
+$193M
Cap. Flow
% of AUM
3.91%
Top 10 Holdings %
Top 10 Hldgs %
46.72%
Holding
190
New
7
Increased
53
Reduced
59
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$17.4M |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$13.1M |
| 3 |
Rush Enterprises Class A
RUSHA
|
+$11.4M |
| 4 |
Credit Acceptance
CACC
|
+$10.8M |
| 5 |
Blue Owl Capital
OWL
|
+$10.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$6.79M |
| 2 |
TCN
Tricon Residential Inc.
TCN
|
+$6.04M |
| 3 |
Sherwin-Williams
SHW
|
+$3.09M |
| 4 |
Apple
AAPL
|
+$2.49M |
| 5 |
Jefferies Financial Group
JEF
|
+$1.82M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 40.58% |
| 2 | Healthcare | 13.65% |
| 3 | Technology | 12.84% |
| 4 | Industrials | 7.53% |
| 5 | Communication Services | 6.95% |
Similar funds
SCA
MCCA
AC
TPCW
DGI
JSTA
PBA
KCM
Beck Mack & Oliver's Q1 2024 Portfolio in Review
As of Q1 2024, Beck Mack & Oliver held 190 positions worth $4.93B, up 15% from $4.3B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Beck Mack & Oliver deployed $193M of net new capital in Q1 2024, opening 7 new positions and adding to 53 existing holdings. Its largest new stake was Smith Douglas Homes: 142,029 shares worth $4.22M.
By sector, the portfolio is most concentrated in Financials at 41% of assets, down from 41% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $6.79M trimmed.
- Beck Mack & Oliver's largest Q1 2024 buy was Smith Douglas Homes: 142,029 shares worth $4.22M.
- Beck Mack & Oliver added most to Amazon in Q1 2024, an estimated $17.4M increase.
- Beck Mack & Oliver's biggest Q1 2024 reduction was Teva Pharmaceuticals, cutting an estimated $6.79M.
- Beck Mack & Oliver fully exited Blue Owl Capital in Q1 2024, selling an estimated $502K.
- Beck Mack & Oliver's ten largest holdings make up 47% of its $4.93B portfolio in Q1 2024.
- Beck Mack & Oliver opened 7 new positions and closed 11 in Q1 2024.
- Beck Mack & Oliver's portfolio value rose 15% quarter-over-quarter to $4.93B.
Based on Beck Mack & Oliver's 13F filing for Q1 2024, filed 14 May 2024.